{"id":22237,"date":"2026-06-17T14:00:00","date_gmt":"2026-06-17T12:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=a930fcfd70b95a164d1fa4394018a83c"},"modified":"2026-06-17T14:00:00","modified_gmt":"2026-06-17T12:00:00","slug":"vedana-therapeutics-launches-with-46-million-series-a-financing-to-advance-next-generation-migraine-therapies","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=22237","title":{"rendered":"Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies"},"content":{"rendered":"

\nTargeting clinically validated pathways to enable patients to achieve freedom from migraine<\/i><\/p>

\nBuilt by the world\u2019s foremost migraine experts and industry leaders<\/i><\/p>

\nFinancing co-led by Westlake BioPartners and Canaan Partners<\/i><\/p>

SEATTLE--(BUSINESS WIRE)--Vedana Therapeutics (\u201cVedana\u201d), a biotechnology company developing next-generation therapies for migraine prevention, today emerged from stealth with $46 million in Series A financing. The financing was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana\u2019s executive team, board, and advisors include leaders who discovered and developed multiple migraine therapies, including approved calcitonin gene-related peptide (CGRP) antibodies and the emerging pituitary adenylate cyclase-activating polypeptide (PACAP) drug class.<\/p><\/a><\/a><\/a><\/a>

\nProceeds from the financing will be used to advance Vedana\u2019s portfolio of internally discovered, potentially best-in-class, subcutaneously delivered antibodies targeting clinically validated pathways for migraine prevention.<\/p>

\n\u201cFirst-generation CGRP therapies were a major step forward in the treatment of migraine, but most patients are still not adequately controlled,\u201d said Anurag Agarwal, Ph.D., co-founder and chief executive officer of Vedana. \u201cWe are now focused on what comes next \u2014 targeting biology beyond CGRP, like PACAP and combinations thereof, to deliver on our vision of migraine freedom for all patients.\u201d<\/p>

\nApproval of multiple CGRP medicines marked the launch of the first generation of specialized therapies for migraine patients. However, two-thirds of the patients are still unable to gain optimal control of their migraine. PACAP, like CGRP, plays a critical role in migraine physiology and is emerging as a complementary approach to treat patients. Based on such clinically validated biology, Vedana has built a portfolio of internally discovered subcutaneously delivered long-acting antibodies. The company\u2019s lead program is the next-generation anti-PACAP antibody, and its second program targets both PACAP and CGRP. While targeting PACAP alone provides a novel approach beyond currently approved drugs, Vedana\u2019s bispecific antibody targeting both PACAP and CGRP could potentially deliver additional efficacy for patients who do not achieve relief with monotherapies.<\/p>

\nCo-founder and chief scientific officer Leon Garcia, Ph.D., added, \u201cVedana was founded by a team that has spent years developing antibody therapies against CGRP and PACAP, giving us deep insight into both the promise and the limitations of existing approaches. Drawing on that experience, we designed the next-generation of highly potent long half-life antibodies, targeting self-injecting options for patients in the convenience of their home.\u201d<\/p>

\n\u201cVedana\u2019s team has an unparalleled track record and has executed efficiently in generating multiple molecules with best-in-class potential,\u201d said Mira Chaurushiya, Ph.D., managing director at Westlake BioPartners. \u201cAs the migraine market continues to evolve, Vedana\u2019s leadership is well positioned to identify and address patient needs.\u201d<\/p>

\n\u201cThe Vedana team represents the deepest concentration of migraine expertise we have seen. Importantly, they bring together the lived experiences from multiple migraine companies and medicines in large and small biotech. They are focused entirely on what the next generation of medicines needs to deliver for patients. We are proud to back them,\u201d said Julie Grant, general partner at Canaan Partners.<\/p>

\nBuilt by the Team Behind Modern Migraine Therapeutics<\/b><\/p>

\nVedana was built by the world\u2019s leading migraine experts and industry leaders with decades of experience across migraine biology, antibody engineering, clinical development, and commercialization.<\/p>

\nVedana\u2019s executive leadership team includes:<\/p>